Articles tagged "Lung transplantation"

2021 American Transplant Congress
Accounting for Survivor Bias in Transplant Benefit Models
E. M. Schnellinger¹, E. Cantu², M. O. Harhay¹, D. E. Schaubel¹, S. E. Kimmel¹, A. J. Stephens-Shields¹
¹Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Department of Surgery, Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: The lung allocation system in the U.S. prioritizes lung transplant candidates based on estimated pre- and post-transplant survival. However, these models do not account…
2021 American Transplant Congress
Pregnancy Outcomes in 39 Lung Transplant Recipients
S. Constantinescu¹, L. A. Coscia², A. Yusuf², S. Rao³, M. J. Moritz⁴
¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Transplant Pregnancy Registry International, Philadelphia, PA, ³University of Virginia Heath System, Charlottesville, VA, ⁴Lehigh Valley Health Network, Allentown, PA
*Purpose: The purpose of this study is to describe 52 pregnancies in 39 lung transplant recipients reporting to the Transplant Pregnancy Registry International (TPRI) from…
2021 American Transplant Congress
Prevalence of Hepatitis E Virus Infection in Solid Organ Transplant Recipients: A Systematic Review and Meta-analysis
P. Hansrivijit¹, A. Trongtorsak², B. Boonpheng³, C. Thongprayoon⁴, W. Cheungpasitporn⁴
¹Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA, ²Department of Internal Medicine, Amita Health Saint Francis Hospital, Evanston, IL, ³Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA, ⁴Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
*Purpose: Hepatitis E virus (HEV) infection is an underdiagnosed disease due to the use of serological assays with low sensitivity. Although most patients with HEV…
2021 American Transplant Congress
Therapeutic Enoxaparin Dosing in Lung Transplant Recipients
S. Finder, M. Morrison, K. B. Harrison, S. A. Heeney
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Enoxaparin 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation is known to increase rates of supratherapeutic anti-Xa levels in lung transplant recipients (LTRs).…
2021 American Transplant Congress
Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay
O. A. Timofeeva¹, J. Choe², M. Alsammak², E. J. Yoon², S. Geier², K. Carney², J. Au², A. Diamond², J. A. Galli², K. Shenoy², A. Mamary², S. Seghal², P. Mullhal², Y. Toyoda², N. Shigemura², F. Cordova², G. Criner², J. Brown²
¹MedStar Georgetown University Hospital, Washington, DC, ²Temple University Hospital, Philadelphia, PA
*Purpose: Development of donor‐specific antibodies (DSA) is associated with poor outcomes in lung transplantation. Patients who are presented with at least probable AMR require treatment;…
2021 American Transplant Congress
Proxies of Ischemia Time Do Not Predict 1-Year Posttransplant Survival
M. Skeans¹, A. Wey¹, E. Lease², C. Lehr³, J. Alcorn⁴, R. Goff⁴, D. Stewart⁴, M. Valapour³
¹SRTR, Minneapolis, MN, ²Univ of Washington, Seattle, WA, ³Cleveland Clinic, Cleveland, OH, ⁴UNOS, Richmond, VA
*Purpose: A barrier to broader distribution of donor organs is a concern that increased donor-to-recipient (DtR) distances could increase ischemia times and compromise posttransplant (PT)…
2021 American Transplant Congress
Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Data from the US Scientific Registry of Transplant Recipients (SRTR)
W. Fitzsimmons¹, J. Erdman², J. Wolfram³, D. Nimke², R. Croy², X. Wang², T. Weaver⁴, D. Schladt⁴
¹University of Illinois at Chicago, College of Pharmacy, Vernon Hills, IL, ²Astellas Pharma, Inc, Northbrook, IL, ³Astellas Pharma Europe BV, Leiden, Netherlands, ⁴Chronic Disease Research Group, Minneapolis, MN
*Purpose: There is currently no FDA approved immunosuppressive regimen for lung transplant (Tx) recipients; however, patients routinely receive a calcineurin inhibitor-based regimen. The SRTR database…
2021 American Transplant Congress
Elexacaftor/ivacaftor/tezacaftor in Lung Transplant Recipients: A Case Series
L. M. Potter¹, B. Vargas², S. M. Rotolo¹, C. McEwen¹, K. Tsui¹
¹University of Chicago Medicine, Chicago, IL, ²Roosevelt University, Chicago, IL
*Purpose: Little data is published describing the safety or efficacy of elexacaftor/ivacaftor/tezacaftor in lung transplant recipients. Even though it is not expected to offer pulmonary…
2021 American Transplant Congress
Lung Transplant Recipients Developing Early DSAs are Characterized by a Shift Towards Memory B Cells Directly After Transplantation
S. Christoph¹, A. Hitz¹, R. Bellmàs Sanz¹, J. Kühne¹, B. Wiegmann², F. Ius², J. Salman², E. Chichelnitskiy¹, T. Siemeni², W. Sommer³, A. Haverich², G. Warnecke³, C. Falk¹
¹Institute of Transplant Immunology, MHH, Hannover, Germany, ²Department of Cardiothoracic, Transplant and Vascular Surgery, MHH, Hannover, Germany, ³Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany
*Purpose: After lung transplantation (LTx), the development of early donor HLA-specific antibodies (eDSA) is associated with antibody-mediated rejection (AMR) and poor graft survival. Since 2013,…
2021 American Transplant Congress
Textbook Outcome: A Novel Metric in Lung Transplantation Outcomes
A. M. Ganapathi¹, B. A. Whitson¹, N. A. Mokadam¹, B. C. Keller², A. Logan¹, G. Brock¹, K. Washburn¹, A. D. Schenk¹
¹Surgery, Ohio State University Wexner Medical Center, Columbus, OH, ²Medicine, Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Lung transplant programs are typically assessed based on 1-/3-year survival, however other factors such as quality of life, freedom from rejection and oxygen, etc.,…